Abstract
Surfactins are mixtures of cyclic lipopeptides consisting of variants of a heptapeptide and a linked β-hydroxy fatty acid with various chain lengths of 13-15 carbon atoms. A lactone bridge between the β-hydroxy functional group of the fatty acid and the carboxy terminal functional component of the peptide chain form their cyclic structures. Such lipopeptides, produced mainly by Bacillus species, possess several remarkable biological effects such as antitumor and antimicrobial activities, some of which are highly promising for utilization in plant disease biocontrol. The strain Bacillus subtilis SZMC 6179J was previously shown to exert significant antifungal properties against various phytopathogenic filamentous fungi; therefore, we characterized the structural features of the surfactins produced by this strain in order to explore the origin of the observed antagonistic effects of this potential biocontrol organism. Bacillus subtilis SZMC 6179J was used to produce surfactins, which were characterized by high-performance liquid chromatography/electrospray ionisation ion trap mass spectrometry (HPLC/ESI-ITMS) techniques after precipitation and extraction steps. The 26 isoforms separated and identified represent three types of known surfactin variants and a fourth, previously unknown group characterised by the replacement of the leucine residue by valine in position 2. The relative amounts of this newly identified surfactin group were below 1%, and their cyclic structures were closed by C13-C15 hydroxy fatty acids. The structural assessment of the isoforms by MS(2) measurements led to the characterisation and description of a new fragmentation mechanism of surfactins. The detected new natural lipoheptapeptide compounds with modified structures have significant potential for biotechnological and biocontrol applications. The complementary ITMS(2) data as well as the described internal fragmentation mechanism obtained from the sodiated surfactin molecules may further facilitate the structural elucidation of cyclic lipopeptides in the future. Copyright © 2016 John Wiley & Sons, Ltd.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
